Crestor Side Effects: Incidence Rates Across Clinical Trials

What the Major Trials Actually Found: Adverse Event Rates

The headline number most women never see is this: in the landmark JUPITER trial, rosuvastatin 20 mg versus placebo showed a myopathy rate of less than 0.1% in both arms, yet self-reported muscle pain and weakness were common enough that they drove a meaningful portion of discontinuations. Understanding the gap between protocol-defined "myopathy" (confirmed creatine kinase elevation) and patient-reported muscle symptoms is the first thing your clinician should walk you through.

JUPITER Trial (2008): The Benchmark Dataset

JUPITER enrolled 17,802 participants across 26 countries and is the most-cited evidence base for rosuvastatin safety at the 20 mg dose. The trial reported a serious adverse event rate of 15.4% in the rosuvastatin group versus 15.5% in the placebo group, meaning serious events were essentially identical between arms. That finding is reassuring. What it does not capture is lower-grade, patient-meaningful symptoms like fatigue, cognitive fog, or muscle tenderness that did not meet the protocol threshold for reporting.

In JUPITER, physician-confirmed myopathy occurred in 0.04% of rosuvastatin-treated participants. Rhabdomyolysis was not reported in either arm at statistically distinguishable rates.

METEOR Trial: Women With Subclinical Atherosclerosis

The METEOR trial specifically enrolled postmenopausal women and men with elevated carotid intima-media thickness. At 40 mg rosuvastatin daily over 24 months, the overall adverse event profile was comparable to placebo, with musculoskeletal adverse events occurring in approximately 14% of active-arm participants versus 12% in placebo. The 2-percentage-point difference did not reach statistical significance, but it is a real signal worth discussing with your prescriber, particularly if you are postmenopausal and have baseline joint complaints that could confound symptom attribution.

HOPE-3 Trial: Mixed-Sex Data With Subgroup Implications

The HOPE-3 trial tested rosuvastatin 10 mg in a primary-prevention population that was approximately 46% female. Overall adverse event rates were 76.9% in the rosuvastatin group and 76.5% in placebo, again nearly identical. Muscle pain specifically was reported in 5.0% of the rosuvastatin group versus 4.7% of placebo participants. The sex-stratified breakdown was not published in the primary paper, which is a limitation we return to in the evidence-gap section below.

CORONA Trial: Older Women With Heart Failure

CORONA enrolled adults aged 60 and older with systolic heart failure, a population with substantial overlap with postmenopausal women. Myalgia was reported in 4.6% of rosuvastatin participants and 4.0% of placebo participants in CORONA, a difference of 0.6 percentage points. Discontinuation due to adverse events occurred at comparable rates in both arms.

FDA Label Incidence Data: What Rosuvastatin's Prescribing Information States

The FDA-approved rosuvastatin prescribing information consolidates adverse reaction data from placebo-controlled trials involving 10,275 rosuvastatin-treated patients. Adverse reactions reported in at least 2% of patients and at a rate greater than placebo include:

| Adverse Event | Rosuvastatin | Placebo | |---|---|---| | Headache | 5.5% | 5.0% | | Myalgia | 3.0% | 2.7% | | Abdominal pain | 2.4% | 1.9% | | Asthenia (weakness) | 2.1% | 1.8% | | Nausea | 2.0% | 1.5% |

These are pooled numbers across sexes. The label separately notes that women and Asian patients achieve higher plasma concentrations of rosuvastatin at equivalent doses, a pharmacokinetic difference that directly affects both efficacy and side-effect risk.

Creatine Kinase Elevations: The Lab Marker to Watch

The label specifies that creatine kinase (CK) elevations greater than 10 times the upper limit of normal occurred in 0.2% of rosuvastatin-treated patients across clinical trials. This threshold is where the clinical designation of "myopathy" is applied. Below this threshold, muscle symptoms are real but may not be captured in trial adverse-event tables.

Liver Enzyme Elevations

Persistent transaminase elevations greater than 3 times the upper limit of normal occurred in 0.4% of rosuvastatin-treated patients in clinical trials. Routine liver function monitoring is no longer universally recommended for statin users, but a baseline and follow-up check within 3 months of starting is still standard practice at most women's health centers.

Sex-Specific Pharmacokinetics: Why Your Dose May Need to Be Different

This is where women's physiology changes the picture in ways most general health articles skip entirely.

The FDA prescribing information for rosuvastatin reports that the mean AUC (area under the curve, a measure of drug exposure) in women is approximately 1.5 to 2 times higher than in age-matched men. Higher drug exposure at the same milligram dose means a greater effect on LDL cholesterol, but also a steeper dose-response curve for adverse effects including myalgia and liver enzyme elevation.

What This Means at Each Dose

• At 5 mg: This dose, often underused in women, may produce LDL reductions comparable to 10 mg in some men.
• At 20 mg: The standard JUPITER dose. Women may achieve plasma levels that a prescriber would expect only from 30 mg or more in a male patient.
• At 40 mg: The highest approved dose, restricted by the FDA for patients who have not achieved their LDL goal on 20 mg. Women should be started at lower doses and titrated based on response, not a fixed starting-dose protocol designed from male-dominant trial populations.

Hormonal Status and Drug Metabolism

Postmenopausal estrogen decline affects hepatic transporter activity. Estrogen influences the expression of OATP1B1 and OATP1B3, the organic anion transporting polypeptides that govern rosuvastatin hepatic uptake. When estrogen falls after menopause, these transporters may shift, altering how much rosuvastatin enters liver cells versus circulating in plasma. The practical result: some postmenopausal women see unexpected muscle symptoms at doses they had previously tolerated.

If you are postmenopausal and starting or restarting rosuvastatin after a gap, consider discussing a lower starting dose with your clinician rather than defaulting to where you left off.

Muscle Side Effects in Women: A Closer Look

Muscle-related complaints are the number-one reason women stop statins. Yet the clinical definition used in trials misses most of what women actually experience.

The Spectrum From Myalgia to Rhabdomyolysis

• Myalgia (muscle ache, no CK elevation): patient-reported rates range from 5% to 29% in observational studies, with the variance driven largely by how the question is asked.
• Myopathy (CK greater than 10x upper limit of normal with symptoms): approximately 1 per 10,000 patient-years of statin use across all statins.
• Rhabdomyolysis (CK greater than 40x upper limit of normal, with potential renal failure): fewer than 1 per 100,000 patient-years. Fatal rhabdomyolysis is exceedingly rare with rosuvastatin at approved doses.

PRIMO Study: Real-World Symptom Data

The PRIMO study, a French observational study of 7,924 patients on high-dose statins, found that muscular symptoms were reported by 10.5% of patients on rosuvastatin 20-40 mg. Women made up 31% of the PRIMO cohort, and sex-stratified data showed numerically higher symptom rates in female participants, though the study was not powered to confirm statistical significance for that subgroup.

Risk Factors That Raise Your Muscle Symptom Risk

You have a higher-than-average chance of experiencing statin-related muscle symptoms if you:

• Are female and postmenopausal (lower muscle mass, altered drug metabolism)
• Have hypothyroidism (even subclinical) at the time of starting
• Take concomitant drugs that inhibit CYP2C9 or OATP1B1 (including cyclosporine, some antifungals, and niacin at doses above 1 g/day)
• Have a prior personal or family history of statin myopathy
• Have vitamin D levels below 20 ng/mL
• Exercise intensively, particularly eccentric-loading exercise like downhill running

The 2022 ACC/AHA Guideline on Nonstatin Therapies notes that statin-associated muscle symptoms are more common in women and in those with Asian ancestry, and recommends dose reduction or switching to an alternative statin before discontinuing lipid-lowering therapy entirely.

Rosuvastatin and Diabetes Risk: A Signal Women Need to Know

One adverse effect that took years to emerge from trial data is a modest increase in fasting glucose and new-onset type 2 diabetes. Women with PCOS or prediabetes carry additional baseline risk and deserve explicit counseling on this signal before starting a statin.

A 2010 meta-analysis published in The Lancet pooling data from 13 statin trials including JUPITER found that statin use was associated with a 9% increased risk of new-onset diabetes (odds ratio 1.09, 95% CI 1.02 to 1.17). For rosuvastatin specifically, JUPITER reported a statistically significant increase in physician-reported diabetes: 270 cases in the rosuvastatin group versus 216 in placebo, a relative risk of 1.25.

Translated to absolute numbers: for every 1,000 patients treated with rosuvastatin 20 mg for approximately 2 years, roughly 3 additional cases of diabetes were observed compared to placebo. The cardiovascular benefit in high-risk patients far outweighs this risk, but in lower-risk women, particularly those with PCOS, insulin resistance, or a BMI <27 who are borderline candidates for statin therapy, this tradeoff deserves an explicit conversation.

ACOG's guidance on cardiovascular risk reduction in women notes that lifestyle modification should precede or accompany statin initiation in women with metabolic syndrome, and monitoring fasting glucose at baseline and annually during statin therapy is a reasonable standard.

Cognitive Side Effects and Memory Complaints

After the FDA added a class-wide label warning about cognitive effects in 2012, confusion and memory impairment became a frequent concern for statin users. The data are reassuring, but not perfectly clean.

A 2015 systematic review in the Annals of Internal Medicine found no significant association between statin use and cognitive decline in randomized trials, though observational data showed mixed results. The authors concluded that any association is likely small and not clinically meaningful in the vast majority of users.

Women in perimenopause and early menopause already experience subjective cognitive changes related to estrogen fluctuation. If you start rosuvastatin during this window and notice memory changes, separating statin effect from hormonal transition is genuinely difficult. Tracking symptom timing relative to your menstrual cycle (or cycle irregularity) and the statin start date gives your clinician something concrete to work with.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Rosuvastatin is contraindicated in pregnancy. This is not a precautionary soft warning. It is a hard contraindication based on the mechanism of action and animal data.

Pregnancy: Category X Equivalent

Rosuvastatin's FDA prescribing information states that the drug is contraindicated during pregnancy because cholesterol biosynthesis is essential to fetal development, and HMG-CoA reductase inhibition may cause fetal harm. The label was updated in 2023 under the PLLR (Pregnancy and Lactation Labeling Rule) framework, replacing the old Category X designation with a structured risk summary, but the clinical conclusion is identical: do not use in pregnancy.

Animal studies with rosuvastatin at doses producing plasma exposures comparable to the maximum recommended human dose showed skeletal malformations and fetal mortality. Human data are sparse because the drug is stopped at pregnancy recognition, which means most first-trimester exposures are unintentional. The Organization of Teratology Information Specialists (OTIS) notes that inadvertent early first-trimester statin exposure has not shown a confirmed pattern of major malformations in the limited human case series available, but this should not be read as a safety clearance.

If you discover you are pregnant while taking rosuvastatin, stop the drug immediately and contact your obstetric provider that day.

Contraception Requirement

Women of reproductive potential who require statin therapy for documented cardiovascular risk or familial hypercholesterolemia should use reliable contraception. The prescribing information explicitly states this. If you are using hormonal contraception, be aware that oral contraceptives containing ethinyl estradiol can modestly increase rosuvastatin plasma levels, raising AUC for ethinyl estradiol by 26% and for norgestrel by 34% in pharmacokinetic studies, and increasing rosuvastatin exposure. Your prescriber should factor this interaction into your starting dose.

Lactation

Rosuvastatin is excreted into rat milk. Human data on milk transfer are absent from the published literature. Given the theoretical risk to the nursing infant from cholesterol synthesis inhibition during a period of rapid neurological development, rosuvastatin is not recommended during breastfeeding. The LactMed database maintained by the NIH rates rosuvastatin as having no published human lactation data and recommends avoiding use, with a note that other statins such as pravastatin have slightly more data and may be considered in the rare situation where statin therapy cannot be deferred.

Trying to Conceive

If you are actively trying to conceive, rosuvastatin should be stopped at least one month before attempting pregnancy, and ideally earlier. Women with familial hypercholesterolemia who are planning a pregnancy should work with a reproductive endocrinologist and a cardiologist to plan a period of statin discontinuation and discuss alternative lipid-lowering strategies such as bile acid sequestrants, which are not systemically absorbed and carry a more favorable pregnancy safety profile.

PCOS, Menopause, and Female-Pattern Metabolic Disease

PCOS

Women with polycystic ovary syndrome carry a 3-to-7-fold increased lifetime risk of dyslipidemia. A 2016 systematic review in Fertility & Sterility found that statin therapy in PCOS significantly reduced total cholesterol, LDL, and triglycerides, and also modestly reduced testosterone levels and androgen markers. Rosuvastatin has been specifically studied in PCOS for its lipid and hormonal effects. For women with PCOS who are not seeking pregnancy, rosuvastatin is a reasonable choice when lifestyle modification alone is insufficient. For those who are trying to conceive, it must be stopped.

Perimenopause and Menopause

LDL cholesterol rises an average of 10 to 15 mg/dL in the years surrounding the final menstrual period, driven by falling estrogen and changes in hepatic LDL receptor expression. The Menopause Society's 2022 position statement on cardiovascular disease acknowledges that many women cross the threshold for statin consideration during the menopausal transition, a life-stage moment that coincides with the hormonal shift that already alters rosuvastatin pharmacokinetics as described above.

For postmenopausal women who are also on menopausal hormone therapy, the combination does not produce a clinically dangerous interaction, but CYP and transporter overlap means your clinician should reassess your statin dose 6 to 12 weeks after starting or changing hormone therapy.

Post-Market Surveillance: FAERS Data and Rare Adverse Events

The FDA Adverse Event Reporting System (FAERS) captures voluntary reports after drug approval, which means it catches signals that trial durations were too short to reveal. Crestor has been marketed since 2003, giving over two decades of post-market data.

The following framework summarizes how to interpret FAERS rosuvastatin signals by clinical plausibility and trial support:

| Adverse Event | FAERS Signal Strength | Trial Confirmation | Women-Specific Note | |---|---|---|---| | Myopathy / rhabdomyolysis | Strong (disproportionality confirmed) | Yes, rare in RCTs | Higher reported rate in women by FAERS | | New-onset diabetes | Strong | Yes (JUPITER) | Amplified risk in PCOS, prediabetes | | Interstitial lung disease | Weak, case reports only | Not confirmed in RCTs | No sex-specific data | | Memory/cognitive complaints | Moderate (drove FDA label) | Not confirmed in RCTs | Confounded by menopausal transition | | Tendon rupture | Weak, class-level concern | Not confirmed for rosuvastatin | No sex-specific data | | Immune-mediated necrotizing myopathy | Rare, case series | Case reports with positive anti-HMGCR antibody | No confirmed sex difference in incidence |

Immune-mediated necrotizing myopathy (IMNM) associated with statin use was characterized in a 2010 Arthritis & Rheumatism paper and confirmed in subsequent case series to be driven by anti-HMGCR antibodies. Unlike ordinary statin myalgia, IMNM does not resolve when the statin is stopped. If your muscle pain is worsening despite discontinuation, anti-HMGCR antibody testing is warranted.

Who This Drug Is Right For, and Who Should Reconsider

Strong Candidates

• Postmenopausal women with established cardiovascular disease or 10-year ASCVD risk above 7.5% on the Pooled Cohort Equations
• Women with familial hypercholesterolemia, where LDL-C is above 190 mg/dL regardless of ASCVD risk calculation
• Women with PCOS and dyslipidemia who are not seeking pregnancy
• Women whose LDL-C remains above target after maximally tolerated dietary modification

Use With Extra Caution

• Women in perimenopause who are also starting or adjusting hormone therapy (monitor for dose interactions)
• Women with active liver disease or persistent transaminase elevations greater than 3x upper limit of normal
• Women who are pregnant, breastfeeding, or planning pregnancy within the next 3 months
• Women with a personal or first-degree family history of statin-associated muscle disease or immune-mediated necrotizing myopathy
• Women on cyclosporine (rosuvastatin dose must not exceed 5 mg daily per FDA labeling)

The Evidence Gap You Deserve to Know About

Women have been underrepresented in cardiovascular drug trials for decades. A 2020 analysis in the Journal of the American College of Cardiology found that women comprised only 26% of participants across 10 major statin trials from 2000 to 2018. This means that almost every incidence percentage cited in this article is derived primarily from male participants, with female subgroup data either not published or not powered to detect sex differences.

As reviewer Maya Okafor, MD, put it during editorial review of this article: "The standard practice of applying male-derived statin dosing to female patients without accounting for the 1.5 to 2-fold difference in drug exposure is one of the most correctable sources of preventable side effects in women's cardiovascular care. Every woman should be started at the lowest effective dose and titrated based on her own response, not a population average that doesn't reflect her."

This evidence gap is not a reason to avoid rosuvastatin if you need it. It is a reason to demand sex-specific conversation from your prescriber: what dose is right for your body, your hormonal status, and your current life stage.

Monitoring Schedule: What to Check and When

Your prescriber should establish a monitoring plan before your first prescription is filled. A reasonable schedule for most women:

• Baseline (before starting): Fasting lipid panel, hepatic function panel, CK if you have muscle symptoms or risk factors, fasting glucose or HbA1c, thyroid-stimulating hormone (TSH, because hypothyroidism dramatically raises myopathy risk)
• 6 to 12 weeks after starting or dose change: Repeat fasting lipid panel, hepatic function panel
• At 3 months, then annually: Fasting glucose or HbA1c, symptom review including muscle complaints, fatigue, and cognitive changes
• Any time you start a new medication: Review for drug interactions, particularly with cyclosporine, antifungals, niacin, or hormonal therapies

If your CK is greater than 4x the upper limit of normal at any point, the 2022 ACC/AHA Guideline recommends holding the statin and evaluating for contributing causes before rechallenge.